Calmark receives SEK 10.7 million through the redemption of warrants with an exercise rate of 98.1%
Calmark Sweden AB (publ) (“Calmark” or “the Company”) carried out a rights issue of shares and free-of-charge warrants during November 2019. The exercise period of the Series TO 2 B subscription warrants was between December 4, 2020, and December 16, 2020, and thus has ended. In total, 2,408,005 TO 2 B warrants were used to subscribe for shares, corresponding to an exercise rate of approximately 98.1 percent.
In total, 2 408 005 subscription warrants, corresponding to approximately 98.1 percent of the total number, were used to subscribe for 2 408 005 B shares at a subscription price of SEK 4.44 per B share. Through the exercise of warrants, Calmark receives proceeds of approximately MSEK 10.7 before issuance costs.
Anna Söderlund, Calmark’s CEO, comments:
“We are absolutely delighted that so many have decided to exercise TO 2 B warrants and subscribe for shares. This will allow us to develop Calmark further, as planned.”
Number of shares and share capital
Through the exercise of warrants, the number of shares in Calmark increases by 2 408 005 B shares, from 20,258,382 to 22 666 387 shares. The share capital increases by approximately SEK 240 800.50, from SEK 2,025,838.20 to approximately SEK 2 266 638.70. For existing shareholders who have not exercised any warrants, the dilution of capital amounts to approximately 10.62 percent and the dilution of votes to approximately 8.94 percent.
Financial advisors
Stockholm Corporate Finance AB is the financial advisor, Stenbergets Avtalslösningar AB is the legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing agent of Calmark in connection with the exercise period.
This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (Regulation (EU) No 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 18:40 CET on December 16, 2020.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information, please contact:
Anna Söderlund, CEO
Telephone: +46 70 214 98 93
E-mail: anna.soderlund@calmark.se
About Calmark Sweden AB (publ)
Calmark is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
About Stockholm Corporate Finance
Stockholm Corporate Finance is a Swedish, independent and privately-owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. www.stockholmcorp.se.